Michael Migden



E-Posters by Michael Migden
42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLTĀ 
42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLTĀ 
Michael R. Midgen; Karl R. Lewis
Efficacy and safety of sonidegib in patients with aggressive and nonaggressive subtypes of locally advanced basal cell carcinoma: Long-term 42-month results from the BOLT Study
Efficacy and safety of sonidegib in patients with aggressive and nonaggressive subtypes of locally advanced basal cell carcinoma: Long-term 42-month results from the BOLT Study
Karl D. Lewis; Nicholas Squittieri; Michael R. Migden